Etazolate (hydrochloride)
Etazolate hydrochloride (SQ 20009) is an orally active, selective inhibitor of type 4 phosphodiesterase (PDE4) with an IC50 of 2 μM. Etazolate hydrochloride is a γ-aminobutyric acid A (GABAA) receptor regulator. Etazolate hydrochloride is an α-secretase activator and induced the production of soluble amyloid precursor protein (sAPPα) . Etazolate hydrochloride, a pyrazolopyridine class derivative, increases cAMP levels. Etazolate hydrochloride has anxiolyticlike, antidepressant-like and anti-inflammatory effects[1][2][3][4][5].
Product Specifications
CAS Number
35838-58-5
Product Name Alternative
SQ 20009; EHT 0202 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H315, H319, H335
Target
GABA Receptor; Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; Neuronal Signaling
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/etazolate-hydrochloride.html
Purity
98.00
Solubility
DMSO : 66.67 mg/mL (ultrasonic)
Smiles
O=C(C1=CN=C2C(C=NN2CC)=C1N/N=C(C)\C)OCC.Cl
Molecular Formula
C14H20ClN5O2
Molecular Weight
325.79
Precautions
H315, H319, H335
References & Citations
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
EFCAB4B (CRACR2A) (NM_001144958) Human Tagged ORF Clone
